Effects of Rosiglitazone on Serum Ghrelin and Peptide YY Levels

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: Female

Summary

We aimed to evaluate the effects of rosiglitazone on serum ghrelin and peptide yy levels in diabetic women.

• Phase: Phase 4

Details

• Lead Sponsor: Baskent University
• Treatments: Rosiglitazone

Criteria

Inclusion Criteria:

• newly diagnosed, drug naive women with type 2 diabetes

Exclusion Criteria:

• presence of severe cardiovascular disease (eg, New York Heart Association class III or IV congestive heart failure or a history of myocardial infarction or stroke)

• presence of thyroid, pituitary, nutritional, hepatic, renal, or neoplastic disorders